Sep 14, 2021 7:00am EDT Matinas BioPharma Announces Webcast of Presentation at the H.C. Wainwright Global Investment Conference
Sep 13, 2021 6:00am EDT Matinas BioPharma Announces Positive Data in the Ongoing EnACT Trial of MAT2203 (Oral Amphotericin B) for the Treatment of Cryptococcal Meningitis, Exceeding the Prespecified Primary Endpoint Threshold
